Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

Richard Adams; Ewan Brown; Louise Brown; Rachel Butler; Stephen Falk; David  Fisher; Richard Kaplan; Phil Quirke; Susan Richman; Leslie Samuel; Jenny Seligman; Matt Seymour; Kai Keen Shui; Harpreet Wasan; Richard Wilson; Tim Maughan

doi:10.1016/S2468-1253(17)30394-1

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

Richard Adams
, Ewan Brown
, Louise Brown
, Rachel Butler
, Stephen Falk
, David Fisher
, Richard Kaplan
, Phil Quirke
, Susan Richman
, Leslie Samuel
, Jenny Seligman
, Matt Seymour
, Kai Keen Shui
, Harpreet Wasan
, Richard Wilson
, Tim Maughan

Aberdeen Centre for Evaluation

Research output: Contribution to journal › Article › peer-review

47 Citations (Scopus)

33 Downloads (Pure)

Original language	English
Pages (from-to)	162–171
Number of pages	9
Journal	The Lancet Gastroenterology & Hepatology
Volume	3
Issue number	3
Early online date	15 Dec 2017
DOIs	https://doi.org/10.1016/S2468-1253(17)30394-1
Publication status	Published - Mar 2018

Bibliographical note

This study was funded by the UK Medical Research Council (MRC)
and National Institute for Health Research (NIHR) Efficacy and
Mechanism Evaluation programme; Cancer Research UK; NIHR
Clinical Trials Research Network; Health and Care Research Wales
(and equivalent in devolved nations); and AstraZeneca Drug Supply
and Distribution. PQ, MS, and SR received programme grant
support from Yorkshire Cancer Research. PQ is an NIHR Senior
Investigator at the Department of Pathology Cardiff and Vale
University Health Board, All Wales Genetics Laboratories, Wales
Cancer Bank. The MRC Clinical Trials Unit at University College
London receives funding from the MRC (programme grant
MC_UU_12023/20).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

colorectal cancer
biomarkers
therapeutic efficacy
EGFR inhibitors

Access to Document

10.1016/S2468-1253(17)30394-1Licence: CC BY

Accepted Manuscript
© The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. https://creativecommons.org/licenses/by/4.0/
Final published version, 417 KBLicence: CC BY

Cite this

Adams, R., Brown, E., Brown, L., Butler, R., Falk, S., Fisher, D., Kaplan, R., Quirke, P., Richman, S., Samuel, L., Seligman, J., Seymour, M., Shui, K. K., Wasan, H., Wilson, R., & Maughan, T. (2018). Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial. The Lancet Gastroenterology & Hepatology, 3(3), 162–171. https://doi.org/10.1016/S2468-1253(17)30394-1

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial. / Adams, Richard; Brown, Ewan; Brown, Louise et al.
In: The Lancet Gastroenterology & Hepatology, Vol. 3, No. 3, 03.2018, p. 162–171.

Research output: Contribution to journal › Article › peer-review

Adams, R, Brown, E, Brown, L, Butler, R, Falk, S, Fisher, D, Kaplan, R, Quirke, P, Richman, S, Samuel, L, Seligman, J, Seymour, M, Shui, KK, Wasan, H, Wilson, R & Maughan, T 2018, 'Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial', The Lancet Gastroenterology & Hepatology, vol. 3, no. 3, pp. 162–171. https://doi.org/10.1016/S2468-1253(17)30394-1

@article{7799814ca83742b28a2d070c17868281,

title = "Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial",

keywords = "colorectal cancer, biomarkers, therapeutic efficacy, EGFR inhibitors",

author = "Richard Adams and Ewan Brown and Louise Brown and Rachel Butler and Stephen Falk and David Fisher and Richard Kaplan and Phil Quirke and Susan Richman and Leslie Samuel and Jenny Seligman and Matt Seymour and Shui, \{Kai Keen\} and Harpreet Wasan and Richard Wilson and Tim Maughan",

note = "This study was funded by the UK Medical Research Council (MRC) and National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation programme; Cancer Research UK; NIHR Clinical Trials Research Network; Health and Care Research Wales (and equivalent in devolved nations); and AstraZeneca Drug Supply and Distribution. PQ, MS, and SR received programme grant support from Yorkshire Cancer Research. PQ is an NIHR Senior Investigator at the Department of Pathology Cardiff and Vale University Health Board, All Wales Genetics Laboratories, Wales Cancer Bank. The MRC Clinical Trials Unit at University College London receives funding from the MRC (programme grant MC\_UU\_12023/20).",

year = "2018",

month = mar,

doi = "10.1016/S2468-1253(17)30394-1",

language = "English",

volume = "3",

pages = "162–171",

journal = "The Lancet Gastroenterology \& Hepatology",

publisher = "Elsevier Limited",

number = "3",

}

TY - JOUR

T1 - Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D)

T2 - a phase 2–3 randomised trial

AU - Adams, Richard

AU - Brown, Ewan

AU - Brown, Louise

AU - Butler, Rachel

AU - Falk, Stephen

AU - Fisher, David

AU - Kaplan, Richard

AU - Quirke, Phil

AU - Richman, Susan

AU - Samuel, Leslie

AU - Seligman, Jenny

AU - Seymour, Matt

AU - Shui, Kai Keen

AU - Wasan, Harpreet

AU - Wilson, Richard

AU - Maughan, Tim

N1 - This study was funded by the UK Medical Research Council (MRC) and National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation programme; Cancer Research UK; NIHR Clinical Trials Research Network; Health and Care Research Wales (and equivalent in devolved nations); and AstraZeneca Drug Supply and Distribution. PQ, MS, and SR received programme grant support from Yorkshire Cancer Research. PQ is an NIHR Senior Investigator at the Department of Pathology Cardiff and Vale University Health Board, All Wales Genetics Laboratories, Wales Cancer Bank. The MRC Clinical Trials Unit at University College London receives funding from the MRC (programme grant MC_UU_12023/20).

PY - 2018/3

Y1 - 2018/3

KW - colorectal cancer

KW - biomarkers

KW - therapeutic efficacy

KW - EGFR inhibitors

U2 - 10.1016/S2468-1253(17)30394-1

DO - 10.1016/S2468-1253(17)30394-1

M3 - Article

VL - 3

SP - 162

EP - 171

JO - The Lancet Gastroenterology & Hepatology

JF - The Lancet Gastroenterology & Hepatology

IS - 3

ER -